Among the various clinical aspects related to the management of hypertension, the choice of blood pressure (BP) targets is probably one of the most challenging. Unfortunately, there is disagreement across the major Hypertension Guidelines on the definition of the most appropriate treatment targets [1–8]. Such discordance might lead to confusion in the clinical practice, based on the perception that evidence from major clinical studies is not interpreted univocally by experts. The situation resembles that occurring for cardiorenal risk reduction in the management of diabetes [9].
